Scarica l'app Stockscreener
5.21
9.22%
0.44
Dopo l'orario di chiusura:
5.29
0.08
+1.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.77
Aprire:
$5.2
Volume 24 ore:
18.06M
Relative Volume:
8.06
Capitalizzazione di mercato:
$1.03B
Reddito:
$191.45M
Utile/perdita netta:
$160.72M
Rapporto P/E:
6.3343
EPS:
0.8225
Flusso di cassa netto:
$-34.44M
1 W Prestazione:
+11.56%
1M Prestazione:
+15.27%
6M Prestazione:
+22.01%
1 anno Prestazione:
+45.53%
Intervallo 1D:
$5.09
$5.45
Intervallo di 1 settimana:
$4.6305
$5.45
Portata 52W:
$3.49
$5.45
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Nome
Arbutus Biopharma Corp
Settore
Industria
Telefono
604-419-3200
Indirizzo
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
5.21 | 943.73M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Iniziato | Jefferies | Hold |
| 2020-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-27 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-07-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-06 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Reiterato | B. Riley FBR | Buy |
| 2019-10-04 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2018-10-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-06 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Ripresa | Chardan Capital Markets | Buy |
| 2018-03-19 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Reiterato | Wedbush | Outperform |
| 2016-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
Mostra tutto
Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie
Arbutus Biopharma (NASDAQ:ABUS) Capital Strategy Draws Attention - Kalkine Media
Why Is Arbutus Biopharma Stock Gaining Friday? - TradingView
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet - StocksToTrade
Why is Arbutus Biopharma stock surging today? - Investing.com
Why is Arbutus Biopharma stock surging today? By Investing.com - Investing.com UK
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Stocktwits
ABUS Looks 90.4% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
Arbutus Biopharma stock surges on $230M buyback plan - Investing.com
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
ABUS Looks 90.4% Undervalued on GF Value™ - GuruFocus
Arbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender Offer - Quiver Quantitative
Arbutus Announces Intent to Repurchase Up to US$230 Million - GlobeNewswire
Arbutus Plans $230 Million Share Buyback After Moderna Deal - MyChesCo
Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims - Law360
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130 - TradingKey
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - Stock Titan
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Arbutus Biopharma earnings matched, revenue topped estimates - Investing.com
Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact - Kalkine Media
ABUS Looks 90.7% Undervalued on GF Value™ Despite Revenue Challe - GuruFocus
What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings - GuruFocus
Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com - Investing.com Nigeria
Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary - TradingView
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Arbutus: Q2 Earnings Snapshot - KVUE
Arbutus Biopharma (ABUS) swings to $164.6M H1 profit on $178.4M Moderna payout - Stock Titan
American Public Education and Arbutus Biopharma Post Notable Stock Returns - MarketsMojo
Arbutus Biopharma (ABUS) Earnings Date and Reports 2026 - MarketBeat
Arbutus Biopharma (ABUS) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - Yahoo Finance
Arbutus Biopharma Corp (I9DN.DU) stock price, news, quote and history - Yahoo Finance Australia
Arbutus Biopharma Corp (I9DN.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arbutus Biopharma (ABUS) Institutional Ownership 2026 - MarketBeat
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Arbutus Biopharma Corp expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADAR1 Capital Management LLC Has $14.10 Million Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
Arbutus Biopharma Corporation $ABUS Shares Acquired by Rubric Capital Management LP - MarketBeat
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Corp (ABUS) Cash Flow - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090 - TradingKey
Arbutus Biopharma Corp (ABUS) Balance Sheet - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.440|Chg%:+0.060 - TradingKey
TradingKey - TradingKey
Arbutus Biopharma Corp (ABUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arbutus Biopharma Corp Azioni (ABUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):